Jump to section
GRAIL's mission is to transform cancer care through early detection.
11% employee growth in 12 months
Detecting cancer early matters a lot. Survival rates are much higher when cancer is diagnosed in earlier stages. However, early screening only exists for a limited number of cancer types and the majority of cancer diagnosis are made later, when survival rates are much lower.
GRAIL is on a mission to improve cancer detection and save lives. By bringing together experts in bioinformatics, clinical science and deep learning, the company is building models from tumour genome sequencing data to provide actionable insights into how multiple types of cancers could be detected early using blood tests.
The development of these blood tests is supported by population-scale clinical studies. GRAIL is building an atlas characterising the levels of 'cell-free nucleic acids' (a key indicator of cancers) in thousands of individuals with and without cancer to help validate their early-stage tests. These will be some of the largest cancer-related studies ever to date. The company has also developed Garelli - a new blood test that has the ability to detect more than 50 types of cancer through a single blood draw, now becoming available on health insurance plans such as Curative Insurance.
Freddie
Company Specialist at Welcome to the Jungle
May 2020
$390m
SERIES D
Dec 2019
$125m
SERIES D
This company has top investors
Bob Ragusa
(CEO, not founder)BSE and MSE from Carnegie Mellon and MBA from University of Connecticut. Over 3 years as a EVP at Accuray and 7 years as COO at Illumina. Currently a Board member at Twist Bioscience.